Biomarker-guided therapy for colorectal cancer: strength in complexity
A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
[HTML][HTML] NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance
F Liu, Y Wei, H Zhang, J Jiang, P Zhang… - Frontiers in oncology, 2022 - frontiersin.org
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion
D Chakravarty, A Johnson, J Sklar… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …
membership following publication or presentation of potentially practice-changing data from …
TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
EY Rosen, DA Goldman, JF Hechtman, R Benayed… - Clinical Cancer …, 2020 - AACR
Purpose: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion–positive
cancers and consequently are now an established standard of care. Little is known …
cancers and consequently are now an established standard of care. Little is known …
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
A Turpin, C Neuzillet, E Colle… - … in medical oncology, 2022 - journals.sagepub.com
Mortality from pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide and
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …
[HTML][HTML] SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a …
Y Li, X Yang, W Zhu, Y Xu, J Ma, C He, F Wang - Cancer Cell International, 2022 - Springer
Background Genes related to the SWItch/sucrose nonfermentable (SWI/SNF) chromatin
remodeling complex are frequently mutated across cancers. SWI/SNF-mutant tumors are …
remodeling complex are frequently mutated across cancers. SWI/SNF-mutant tumors are …
[HTML][HTML] Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
S O'Haire, F Franchini, YJ Kang, J Steinberg… - Scientific reports, 2023 - nature.com
NTRK gene fusions are rare somatic mutations found across cancer types with promising
targeted therapies emerging. Healthcare systems face significant challenges in integrating …
targeted therapies emerging. Healthcare systems face significant challenges in integrating …
[HTML][HTML] Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently
approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine …
approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine …
Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature
J Lasota, M Chlopek, J Lamoureux… - The American journal …, 2020 - journals.lww.com
This study was undertaken to determine the frequency, and the clinicopathologic and
genetic features, of colon cancers driven by neurotrophic receptor tyrosine kinase (NTRK) …
genetic features, of colon cancers driven by neurotrophic receptor tyrosine kinase (NTRK) …
RNA sequencing reveals novel oncogenic fusions and depicts detailed fusion transcripts of FN1-FGFR1 in phosphaturic mesenchymal tumors
X Liu, X Yin, D Li, K Li, H Zhang, J Lu, L Zhou, J Gao… - Modern Pathology, 2023 - Elsevier
Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms of soft tissue or bone.
Although previous studies revealed that approximately 50% of PMTs harbor FN1:: FGFR1 …
Although previous studies revealed that approximately 50% of PMTs harbor FN1:: FGFR1 …